drugset / Trial / NCT05472558
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
NaSingle-groupOpen-labelTreatment
Summary
To study the safety and effectiveness of cord blood-derived CAR-NK cells targeting CD19 in patients with B-cell non-Hodgkin's lymphoma
Timeline
- Start
- 2022-07-26
- Primary completion
- 2025-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19 CAR-NK | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | anti-CD19 CAR-NK | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | anti-CD19 CAR-NK | Cell therapy | 4e+06 cells/kg | Intravenous |